Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:SNOA

Sonoma Pharmaceuticals Earnings Date & Estimates

Sonoma Pharmaceuticals logo
$1.11 -0.02 (-1.77%)
As of 03:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sonoma Pharmaceuticals is estimated to report earnings on Monday, November 16, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is expected to post earnings of -$0.10 per share on revenue of $5.29 million. In the same quarter a year earlier Sonoma Pharmaceuticals reported -$0.13 per share. Sonoma Pharmaceuticals last reported on August 6, 2026, posting $0.02 per share and beating the -$0.30 consensus estimate. Sonoma Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.10
Expected Revenue
$5.29 million
Prior-Year EPS
-$0.13

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
$0.02 (Beat by +$0.32)
Last Quarter Revenue
$6.41 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Sonoma Pharmaceuticals Earnings FAQ

Sonoma Pharmaceuticals (NASDAQ:SNOA) is estimated to report earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Sonoma Pharmaceuticals to post earnings of -$0.10 per share for the quarter.

The consensus revenue estimate for Sonoma Pharmaceuticals is $5.29 million for the quarter.

Sonoma Pharmaceuticals Earnings Headlines

Sonoma Pharmaceuticals (NASDAQ:SNOA) vs. Vanda Pharmaceuticals (NASDAQ:VNDA) Financial Contrast
November 7 at 5:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183931
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Decrease in Short Interest
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172698
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 10 at 1:00 AM  |  Weiss Ratings (Ad)
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-cancels-adjourned-special-stockholder-meeting?utm_source=marketbeat.com&utm_medium=referral
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
August 6, 2026  |  benzinga.comhttps://www.benzinga.com/markets/earnings/26/08/60993290/sonoma-pharmaceuticals-turns-ebitda-positive-for-first-time-with-record-quarterly-revenue?utm_source=snapi
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sonoma-pharmaceuticals-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment.

The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.

Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences and adopted its current name in 2016. The company has served customers in the United States and international markets through a combination of direct sales, commercial partnerships and distributors.

View Sonoma Pharmaceuticals Profile
Earnings Tools